Sphingosine 1-phosphate receptor 2 (S1P 2 ) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy

Ototoxic drugs, such as platinum-based chemotherapeutics, often lead to permanent hearing loss through apoptosis of neuroepithelial hair cells and afferent neurons of the cochlea. There is no approved therapy for preventing or reversing this process. Our previous studies identified a G protein-coupled receptor (GPCR), S1P 2 , as a potential mediator of otoprotection. We therefore sought to identify a pharmacological approach to prevent cochlear degeneration via activation of S1P 2 . The cochleae of S1pr2 −/− knockout mice were evaluated for accumulation of reactive oxygen species (ROS) with a nitro blue tetrazolium (NBT) assay. This showed that loss of S1P 2 results in accumulation of ROS that precedes progressive cochlear degeneration as previously reported. These findings were supported by in vitro cell-based assays to evaluate cell viability, induction of apoptosis and accumulation of ROS following activation of S1P 2 in the presence of cisplatin. We show for the first time, that activation of S1P 2 with a selective receptor agonist increases cell viability and reduces cisplatin-mediated cell death by reducing ROS. Cumulatively, these results suggest that S1P 2 may serve as a therapeutic target for attenuating cisplatin-mediated ototoxicity.